A Phase 3, Randomized, Double-blind, Active Controlled Noninferiority Study Evaluating the Efficacy, Safety, and Tolerability of Cefepime/VNRX-5133 in Adults With Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis

ClinicalTrials.gov processed this data on May 1, 2024. Link to the current ClinicalTrials.gov record.

Recruitment Status

COMPLETED - HAS RESULTS
 (See Contacts and Locations)
Verified March 2024 by Venatorx Pharmaceuticals, Inc.

Sponsor

Venatorx Pharmaceuticals, Inc.

Information Provided by (Responsible Party)

Venatorx Pharmaceuticals, Inc.

Clinicaltrials.gov Identifier

NCT03840148
Other Study ID Numbers: VNRX-5133-201
First Submitted: February 6, 2019
First Posted: February 15, 2019
Results First Posted: May 29, 2024
Last Update Posted: May 29, 2024
Last Verified: March 2024
History of Changes

Listing a study on this site does not mean it has been evaluated by the U.S. Federal Government. The safety and scientific validity of a study listed on ClinicalTrials.gov is the responsibility of the study sponsor and investigators. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.

ClinicalTrials.gov, a resource provided by the U.S. National Library of Medicine (NLM), is a registry and results information database of clinical research studies sponsored or funded by a broad range of public and private organizations around the world. Not all studies listed on ClinicalTrials.gov are funded by the National Institutes of Health (NIH) or other agencies of the U.S. Federal Government. Not all listed studies are regulated and/or reviewed by the U.S. Food and Drug Administration or other governmental entities.

Information on ClinicalTrials.gov is provided by study sponsors and investigators, and they are responsible for ensuring that the studies follow all applicable laws and regulations. NLM staff do not verify the scientific validity or relevance of the submitted information beyond a limited quality control review for apparent errors, deficiencies, or inconsistencies.

Choosing to participate in a study is an important personal decision. Before you participate in a study, discuss all options with your health care provider and other trusted advisors. For more information about participating in clinical studies, see Learn About Clinical Studies, which includes questions that you might want to ask before deciding to participate in a study.

For more information about using the information on ClinicalTrials.gov, please also see Terms and Conditions.

See also the Web Policies and Notices for the NIH web site.

Study Description

Not Provided
Condition or Disease Intervention/Treatment
  • Urinary Tract Infections
  • Acute Pyelonephritis
  • Drug: Cefepime/VNRX-5133 (taniborbactam)
  • Drug: Meropenem

Study Design

Study TypeInterventional
Actual Enrollment661 participants
Design AllocationRandomized
Interventional ModelParallel Assignment
MaskingDouble
Primary PurposeTreatment
Official TitleA Phase 3, Randomized, Double-blind, Active Controlled Noninferiority Study Evaluating the Efficacy, Safety, and Tolerability of Cefepime/VNRX-5133 in Adults With Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis
Study Start DateAugust 7, 2019
Actual Primary Completion DateDecember 14, 2021
Actual Study Completion DateDecember 14, 2021

Groups and Cohorts

Group/ CohortIntervention/ Treatment
  • Cefepime/VNRX-5133 (taniborbactam)
    • Cefepime/VNRX-5133 administered q8h intravenously (IV) over a 2-hour period.
  • Drug: Cefepime/VNRX-5133 (taniborbactam)
    • Cefepime/VNRX-5133 administered q8h intravenously (IV) over a 2-hour period for 7 days (up to 14 days for patients with bacteremia). Patients will also receive meropenem placebo administered via IV over 30 minutes.
  • Meropenem
    • Meropenem will be administered q8h IV over 30 minutes.
  • Drug: Meropenem

    Outcome Measures

    Primary Outcome Measures

    1. Composite Success at Test of Cure (TOC) in the Microbiological Intent-to-treat (microITT) Population [Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)]
      Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10^5 CFU/mL) is eradicated to <10^3 CFU/mL. Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

    Secondary Outcome Measures

    1. Microbiologic Success at Test of Cure (TOC) in the microITT Population [Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)]
      Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10^5 CFU/mL) is eradicated to <10^3 CFU/mL.
    2. Clinical Success at Test of Cure (TOC) in the microITT Population [Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)]
      Symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
    3. Composite Success at Test of Cure (TOC) in the Extended Microbiological Intent-to-treat (emicroITT) Population [Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)]
      Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10^5 CFU/mL) is eradicated to <10^3 CFU/mL. Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
    4. Composite Success at End of Treatment (EOT) in the microITT Population [Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)]
      Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10^5 CFU/mL) is eradicated to <10^3 CFU/mL. Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
    5. Microbiological Success at End of Treatment (EOT) in the microITT Population [Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)]
      Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10^5 CFU/mL) is eradicated to <10^3 CFU/mL.
    6. Clinical Success at End of Treatment (EOT) in the microITT Population [Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)]
      Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
    7. Composite Success at Late Follow Up (LFU) in the microITT Population [Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)]
      Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10^5 CFU/mL) is eradicated to <10^3 CFU/mL. Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
    8. Microbiological Success at Late Follow Up (LFU) in the microITT Population [Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)]
      Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10^5 CFU/mL) is eradicated to <10^3 CFU/mL.
    9. Clinical Success at Late Follow Up (LFU) in the microITT Population [Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)]
      Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
    10. Investigator Opinion of Clinical Success at Test of Cure (TOC) in the microITT Population [Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)]
      The proportion of patients with clinical success based on investigator opinion at TOC.
    11. Composite Success in Patients With Cefepime-Resistant Pathogens at End of Treatment (EOT) in the microITT Population [Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)]
      Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10^5 CFU/mL) is eradicated to <10^3 CFU/mL. Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
    12. Microbiologic Success in Patients With Cefepime-Resistant Pathogens at End of Treatment (EOT) in the microITT Population [Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)]
      Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10^5 CFU/mL) is eradicated to <10^3 CFU/mL.
    13. Clinical Success in Patients With Cefepime-Resistant Pathogens at End of Treatment (EOT) in the microITT Population [Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)]
      Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
    14. Composite Success in Patients With Cefepime-Resistant Pathogens at Test of Cure (TOC) in the microITT Population [Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)]
      Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10^5 CFU/mL) is eradicated to <10^3 CFU/mL. Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
    15. Microbiologic Success in Patients With Cefepime-Resistant Pathogens at Test of Cure (TOC) in the microITT Population [Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)]
      Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10^5 CFU/mL) is eradicated to <10^3 CFU/mL.
    16. Clinical Success in Patients With Cefepime-Resistant Pathogens at Test of Cure (TOC) in the microITT Population [Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)]
      Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
    17. Composite Success in Patients With Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the microITT Population [Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)]
      Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10^5 CFU/mL) is eradicated to <10^3 CFU/mL. Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
    18. Microbiologic Success in Patients With Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the microITT Population [Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)]
      Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10^5 CFU/mL) is eradicated to <10^3 CFU/mL.
    19. Clinical Success in Patients With Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the microITT Population [Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)]
      Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
    20. Composite Success at End of Treatment (EOT) in the Microbiologically-Evaluable (ME) Population [Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)]
      Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10^5 CFU/mL) is eradicated to <10^3 CFU/mL. Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
    21. Microbiologic Success at End of Treatment (EOT) in the ME Population [Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)]
      Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10^5 CFU/mL) is eradicated to <10^3 CFU/mL.
    22. Composite Success at Test of Cure (TOC) in the ME Population [Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)]
      Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10^5 CFU/mL) is eradicated to <10^3 CFU/mL. Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
    23. Microbiologic Success at Test of Cure (TOC) in the ME Population [Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)]
      Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10^5 CFU/mL) is eradicated to <10^3 CFU/mL.
    24. Composite Success at Late Follow Up (LFU) in the ME Population [Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)]
      Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10^5 CFU/mL) is eradicated to <10^3 CFU/mL. Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
    25. Microbiologic Success at Late Follow Up (LFU) in the ME Population [Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)]
      Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10^5 CFU/mL) is eradicated to <10^3 CFU/mL.
    26. Composite Success in Patients With Cefepime-Resistant Pathogens at the End of Treatment (EOT) in the ME Population [Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)]
      Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10^5 CFU/mL) is eradicated to <10^3 CFU/mL. Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
    27. Microbiologic Success in Patients With Cefepime-Resistant Pathogens at the End of Treatment (EOT) in the ME Population [Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)]
      Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10^5 CFU/mL) is eradicated to <10^3 CFU/mL.
    28. Composite Success in Patients With Cefepime-Resistant Pathogens at Test of Cure (TOC) in the ME Population [Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)]
      Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10^5 CFU/mL) is eradicated to <10^3 CFU/mL. Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
    29. Microbiologic Success in Patients With Cefepime-Resistant Pathogens at Test of Cure (TOC) in the ME Population [Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)]
      Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10^5 CFU/mL) is eradicated to <10^3 CFU/mL.
    30. Composite Success in Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the ME Population [Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)]
      Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10^5 CFU/mL) is eradicated to <10^3 CFU/mL. Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
    31. Microbiologic Success in Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the ME Population [Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)]
      Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10^5 CFU/mL) is eradicated to <10^3 CFU/mL.
    32. Clinical Success at End of Treatment (EOT) in the Clinically Evaluable (CE) Population [Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)]
      Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
    33. Clinical Success at Test of Cure (TOC) in the CE Population [Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)]
      Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
    34. Clinical Success at Late Follow Up (LFU) in the CE Population [Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)]
      Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
    35. Clinical Success in Patients With Cefepime-Resistant Pathogens at End of Treatment (EOT) in the CE Population [Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)]
      Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
    36. Clinical Success in Patients With Cefepime-Resistant Pathogens at Test of Cure (TOC) in the CE Population [Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)]
      Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
    37. Clinical Success in Patients With Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the CE Population [Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)]
      Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
    38. Per-Pathogen Microbiologic Eradication at End of Treatment (EOT) in the microITT Population [Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)]
      Per-pathogen eradication by baseline gram-negative pathogens. The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.
    39. Per-Pathogen Microbiologic Eradication at Test of Cure (TOC) in the microITT Population [Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)]
      Per-pathogen eradication by baseline gram-negative pathogens. The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.
    40. Per-Pathogen Microbiologic Eradication at Late Follow Up (LFU) in the microITT Population [Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)]
      Per-pathogen eradication by baseline gram-negative pathogens. The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.
    41. Per-Pathogen Microbiologic Eradication in Patients With Cefepime-Resistant Pathogens at End of Treatment (EOT) in the microITT Population [Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)]
      Per-pathogen eradication by baseline gram-negative pathogens (only pathogens identified 10 or more times are reported). The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.
    42. Per-Pathogen Microbiologic Eradication in Patients With Cefepime-Resistant Pathogens at Test of Cure (TOC) in the microITT Population [Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)]
      Per-pathogen eradication by baseline gram-negative pathogens (only pathogens identified 10 or more times are reported). The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.
    43. Per-Pathogen Microbiologic Eradication in Patients With Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the microITT Population [Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)]
      Per-pathogen eradication by baseline gram-negative pathogens (only pathogens identified 10 or more times are reported). The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.
    44. Per-Pathogen Microbiologic Eradication at End of Treatment (EOT) in the ME Population [Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)]
      Per-pathogen eradication by baseline gram-negative pathogens. The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.
    45. Per-Pathogen Microbiologic Eradication at Test of Cure (TOC) in the ME Population [Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)]
      Per-pathogen eradication by baseline gram-negative pathogens. The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.
    46. Per-Pathogen Microbiologic Eradication at Late Follow Up (LFU) in the ME Population [Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)]
      Per-pathogen eradication by baseline gram-negative pathogens. The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.
    47. Per-Pathogen Microbiologic Eradication in Patients With Cefepime-Resistant Pathogens at End of Treatment (EOT) in the ME Population [Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)]
      Per-pathogen eradication by baseline gram-negative pathogens (only pathogens identified 10 or more times are reported). The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.
    48. Per-Pathogen Microbiologic Eradication in Patients With Cefepime-Resistant Pathogens at Test of Cure TOC in the ME Population [Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)]
      Per-pathogen eradication by baseline gram-negative pathogens (only pathogens identified 10 or more times are reported). The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.
    49. Per-Pathogen Microbiologic Eradication in Patients With Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the ME Population [Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)]
      Per-pathogen eradication by baseline gram-negative pathogens (only pathogens identified 10 or more times are reported). The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.

    Eligibility Criteria

    Ages Eligible for Study 18 Years and Older (Adult, Older Adult)
    Sexes Eligible for Study All
    Accepts Healthy Volunteers No
    Inclusion Criteria
    • Adult male and female
    • Documented diagnosis of pyuria
    • Documented diagnosis of cUTI or Acute Pyelonephritis (AP)
    Exclusion Criteria
    • Receipt of effective antibacterial drug therapy for cUTI for more than 24 hours during the previous 72 hours prior to randomization
    • A urine culture result is resistant to meropenem or a gram negative pathogen is not identified or more than 2 microorganisms are isolated or a confirmed fungal UTI is identified
    • Required use of nonstudy systemic bacterial therapy
    • Suspected or confirmed prostatitis or urinary tract symptoms attributable to sexually transmitted disease
    • Patients with perinephric or renal abscess
    • Patients with renal transplantation or receiving hemodialysis or peritoneal dialysis
    • Abnormal labs

    Contacts and Locations

    Sponsors and Collaborators Venatorx Pharmaceuticals, Inc.
    Locations
    • Site 184003 | Buena Park, California, United States, 90620
    • Site 184002 | Chula Vista, California, United States, 91911
    • Site 184001 | La Mesa, California, United States, 91942
    • 184012 | Northridge, California, United States, 91324
    • Site 103203 | Córdoba, Argentina, X5016KEH
    • Site 107601 | Belo Horizonte, Brazil, 30150-221
    • Site 107608 | San Paolo, Brazil, 04039-901
    • Site 110009 | Gabrovo, Bulgaria, 5300
    • Site 110002 | Pleven, Bulgaria, 5800
    • Site 110007 | Plovdiv, Bulgaria, 4003
    • Site 110003 | Ruse, Bulgaria, 7002
    • Site 110010 | Sofia, Bulgaria, 1407
    • Site 110004 | Sofia, Bulgaria, 1606
    • Site 110005 | Sofia, Bulgaria, 1606
    • Site 110008 | Sofia, Bulgaria, 1606
    • Site 110001 | Veliko Tarnovo, Bulgaria, 5000
    • Site 156022 | Baotou, China, 014010
    • Site 156002 | Beijing, China, 100034
    • Site 156006 | Beijing, China, 100050
    • Site 156015 | Chendu, China, 610041
    • Site 156011 | Chongqing, China, 400016
    • Site 156012 | Chongqing, China, 400038
    • Site 156004 | Dalian, China, 116023
    • Site 156030 | Fujian, China, 362202
    • Site 156014 | Guangdong, China, 515041
    • Site 156027 | Guangdong, China, 518035
    • Site 156025 | Guangzhou, China, 510120
    • Site 156018 | Guiyang, China, 550002
    • Site 156003 | Nanchang, China, 330006
    • Site 156005 | Nanjing, China, 156005
    • Site 156008 | Nanjing, China, 210008
    • Site 156007 | Nanjing, China, 210009
    • Site 156013 | Ningbo, China, 315010
    • Site 156028 | Shandong, China, 276000
    • Site 156017 | Shanghai, China, 200025
    • Site 156016 | Shijiazhuang, China, 050000
    • Site 156020 | Tianjin, China, 300192
    • Site 156010 | Xiamen, China, 361003
    • Site 156029 | Ürümqi, China, 830054
    • Site 119103 | Split, Croatia, 21000
    • Site 119101 | Zagreb, Croatia, 10000
    • Site 119106 | Zagreb, Croatia, 10000
    • Site 134801 | Budapest, Hungary, 1204
    • Site 134803 | Nyiregyhaza, Hungary, 4400
    • Site 134804 | Szeged, Hungary, 6725
    • Site 142803 | Daugavpils, Latvia, LV-5417
    • Site 142804 | Riga, Latvia, LV-1002
    • Site 142801 | Riga, Latvia, LV-1038
    • Site 148402 | Colima, Mexico, 28018
    • Site 148401 | Guadalajara, Mexico, 44280
    • Site 160403 | Cuzco, Peru, 84
    • Site 160410 | Lima, Peru, 29
    • Site 160406 | Lima, Peru, 41
    • Site 160404 | Trujillo, Peru, TRUJ 01
    • Site 164204 | Bucharest, Romania, 050653
    • Site 164206 | Bucuresti, Romania, 010825
    • Site 164205 | Bucuresti, Romania, 020125
    • Site 164201 | Craiova, Romania, 200642
    • Site 164307 | Moscow, Russian Federation, 117593
    • Site 164301 | Penza, Russian Federation, 440026
    • Site 164308 | Pyatigorsk, Russian Federation, 357500
    • Site 164311 | Rostov-on-Don, Russian Federation, 344011
    • Site 164303 | Sankt Peterburg, Russian Federation, 194044
    • Site 164302 | Saratov, Russian Federation, 410054
    • Site 189001 | Belgrade, Serbia, 11000
    • Site 189002 | Belgrade, Serbia, 11080
    • Site 179207 | Adapazarı, Turkey, 54100
    • Site 179203 | Bornova, Turkey, 35040
    • Site 179202 | Bostanci, Turkey, 61080
    • Site 179204 | Diyarbakır, Turkey, 21280
    • Site 179205 | Çankaya, Turkey, 06800
    • Site 180404 | Dnipro, Ukraine, 49005
    • Site 180408 | Ivano-Frankivs'k, Ukraine, 76014
    • Site 180402 | Kharkiv, Ukraine, 6111
    • Site 180406 | Kyiv, Ukraine, 02125
    • Site 180401 | Luts'k, Ukraine, 43000
    • Site 180403 | Vinnytsia, Ukraine, 21018
    • Site 180407 | Zaporizhzhya, Ukraine, 69600

    Study Documents (Full Text)

    More Information

    Additional Relevant MeSH Terms

    • Infections
    • Communicable Diseases
    • Urinary Tract Infections
    • Pyelonephritis
    • Disease Attributes
    • Pathologic Processes
    • Urologic Diseases
    • Female Urogenital Diseases
    • Female Urogenital Diseases and Pregnancy Complications
    • Urogenital Diseases
    • Male Urogenital Diseases
    • Nephritis, Interstitial
    • Nephritis
    • Kidney Diseases
    • Pyelitis